Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours
Status:
Not yet recruiting
Trial end date:
2023-01-30
Target enrollment:
Participant gender:
Summary
This is the 'first-in-human' clinical trial of the Investigational Medicinal Product (IMP),
Tablet formulation for Oral dosing of MSP008-22, a molecule (new chemical entity) with
anticancer properties.